Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.
Montoya A, Amaya CN, Belmont A, Diab N, Trevino R, Villanueva G, Rains S, Sanchez LA, Badri N, Otoukesh S, Khammanivong A, Liss D, Baca ST, Aguilera RJ, Dickerson EB, Torabi A, Dwivedi AK, Abbas A, Chambers K, Bryan BA, Nahleh Z.
Montoya A, et al. Among authors: khammanivong a.
Oncotarget. 2017 Jan 24;8(4):6446-6460. doi: 10.18632/oncotarget.14119.
Oncotarget. 2017.
PMID: 28031536
Free PMC article.